市場調查報告書

全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場:開發平台治療藥,診斷技術,治療方法,各地區 - 成長,趨勢,預測(2018年∼2023年)

Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 649745
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場:開發平台治療藥,診斷技術,治療方法,各地區 - 成長,趨勢,預測(2018年∼2023年) Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場在2018年到2023這段調查期間中,預測將以25.0%的年複合成長率成長。糖尿病及肥胖症的盛行率上升,研究開發的投資增加等,促進了該市場的成長。就各地區來看,新醫療技術的引進率高,高度優先於研究和開發活動的健全醫療保健基礎設施使得美國興起為最大市場。

本報告提供全球非酒精性脂肪性肝炎(NASH)市場調查,提供市場概要,各技術·用途·各地區的市場趨勢,市場規模的變化與預測,成長要素·阻礙因素以及市場機會·課題分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 成長要素
    • NASH療法的利潤管道
    • 全球性糖尿病和肥胖人口的患病率上升
    • 新型生物標誌物技術的出現和肝活檢技術的改進
  • 阻礙因素
    • 缺乏非酒精性脂肪肝病(NAFLD)的有效診斷
    • 治療領域的技術進步停頓
  • 市場機會
  • 主要課題

第7章 非酒精性脂肪性肝炎(NASH)市場:各市場區隔

  • 開發平台治療藥物別
    • 第三階段試驗
      • 二乙酸(OCA)
      • Aramchol(花生酰胺膽鹼酸)
      • Saroglitazar
      • Elafibranor
      • 其他
  • 各診斷技術
    • 成像
    • 肝臟切片檢查
    • 生物標記診斷
    • 其他
  • 各治療法
    • 藥物療法
    • 胰島素抗性改善治療
    • 抗細胞因子治療
    • 外科手術
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 競爭情形

  • 合併·收購分析
  • 協定·聯盟·合作
  • 新產品的上市

第9章 主要企業

  • AstraZeneca PLC
  • Conatus Pharmaceuticals, Inc.
  • Enzo Biochem, Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals, Inc.
  • Novo Nordisk A/S

第10章 市場未來展望

第11章 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 67936

The Hepatitis Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period. Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver and liver failure, which can be fatal.

Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.

According to the World Health Organization (WHO), globally, 500 million people are estimated to be infected with hepatitis B or C. About 1.5 million people die in a year due to hepatitis infection, 1 in every 3 people get infected and most of the infected people do not know about it due to dormant symptoms. In addition, in European Hepatitis B and C affect millions of people. In addition, According to the European Centre for Disease Prevention and Control (ECDC), estimates an overall incidence of hepatitis B is 1.49 (Per 100,000), hepatitis c is 8.7 (Per 100,000) in the member states of the European Union (EU) and high prevalence in people who inject drugs.

An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market.

Key Market Trends

Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market

  • Hepatitis C is a liver infection which is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Acute hepatitis C occurs within the first 6 months after individual is exposed to the hepatitis C virus and chronic hepatitis C can be a lifelong infection with the hepatitis C virus if left untreated.
  • According to World Health Organization (WHO), hepatitis C virus (HCV) infection affects over 70 million people globally, and about 3.5 million Americans have hepatitis C virus (HCV) infection among them approximately 3.2 million have chronic (long-term) infection.
  • Hepatitis C segment holds a significant market share in the hepatitis therapeutics market and is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions and the growing availability of effective drug regimens in the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC), estimates about 2.4 million people are living with hepatitis C in the United States and approximately 850,000 people in this region estimated to be living with hepatitis B. In addition, 67% of persons infected with hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advance therapeutics and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited and Cipla, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Viral Hepatitis
    • 4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
    • 4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 Poor Reimbursement Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Hepatitis A
    • 5.1.2 Hepatitis B
    • 5.1.3 Hepatitis C
    • 5.1.4 Hepatitis D
    • 5.1.5 Other Types
  • 5.2 By Drug Class
    • 5.2.1 Interferon
    • 5.2.2 Monoclonal Antibody
    • 5.2.3 Non-structural protein 5A (NS5A) inhibitors
    • 5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
    • 5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
    • 5.2.6 Multi Class Combination
    • 5.2.7 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East-and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co., Inc
    • 6.1.2 Gilead Sciences, Inc
    • 6.1.3 AbbVie Inc
    • 6.1.4 Bristol Myers Squibb Company
    • 6.1.5 F. Hoffmann-La Roche, Ltd
    • 6.1.6 LAURUS Labs
    • 6.1.7 Zydus Cadila
    • 6.1.8 Hetero Healthcare Limited
    • 6.1.9 NATCO Pharma Limited
    • 6.1.10 Cipla, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top